Skip to content

Neuroplasticity: all studies

Page 102 of 178: studies 1,011 to 1,020 of 1,773, newest first. Back to the neuroplasticity overview

Research

Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment

Medical Science Monitor June 30, 2025 Andrzej Silczuk, Robert Madejek, Tytus Koweszko et al. 4 citations

Psychedelics, derived from the Greek words "psyche" (soul) and "deloun" (revealing), are substances historically and currently considered "soul-revealing". Also termed hallucinogens due to their impact on sensory perception, they are further categorized into hallucinogens, such as lysergic acid diethylamide (LSD), psilocybin, and mescaline; entactogens or empathogens, such as...

DOI: 10.12659/msm.948302 (opens in new tab) Mental health Medline Psychotherapist Intensive care medicine

Ketamine-From an Anesthetic to a Psychiatric Drug: Mechanisms of Action, Clinical Applications and Potential Risks.

Molecules June 30, 2025 Ewa Gibuła-Tarłowska, Anna Wiszniewska, Magdalena Turyk et al. 10 citations

Ketamine, originally developed as an anesthetic, is gaining increasing attention due to its multifaceted pharmacological properties. In addition to its use in anesthesia, ketamine exerts potent analgesic effects via N-methyl-D-aspartate (NMDA) receptor antagonism, modulating pain perception and reducing central sensitization, particularly in chronic and neuropathic pain conditions. Emerging...

Evaluating Psilocybin as a Treatment for Neuropsychiatric Symptoms in Parkinson’s Disease

Global Journal of Medical Research June 28, 2025 Norman W. Barton

Parkinson’s Disease (PD) is a progressive neurodegenerative disorder marked by motor symptoms due to dopaminergic degeneration and non-motor symptoms such as depression, anxiety, and cognitive impairment, which significantly affect patients' quality of life. Traditional dopaminergic therapies address motor symptoms but offer limited efficacy for neuropsychiatric manifestations. Psilocybin, a...

Cases of Unconventional Information Flow Across the Mind-Body Interface

Mind and Matter June 24, 2025 Karina Kofman, Michael Levin

Neuroscience, and behavioral science more broadly, seek to characterize the relationship between functional cognition and the underlying processes operating in living tissue. The current paradigm focuses heavily on the brain, and specific mechanisms thought to underlie mental content and capabilities. One of the most interesting approaches to any field, which often leads to progress, is to...

Substance use disorders (SUDs) in Latin America and the Caribbean: a narrative review of native medicinal plants as alternative therapies

Beni-Suef University Journal of Basic and Applied Sciences June 20, 2025 Danladi Chiroma Husaini, Joel H. Chiroma, Innocent Ejiofor Nwachukwu et al.

Abstract Background Latin America and the Caribbean region are currently faced with the challenges of drug and substance use leading to violence and crime, especially among the younger populations. The complex nature of substance use disorder (SUD), the cost and adverse effects of conventional therapies, the deeply rooted cultural practices of medicinal plants usage, and the abundance of...

DOI: 10.1186/s43088-025-00653-7 (opens in new tab) Traditional medicine Medicinal plants

MeCP2 prevents against sustained ketamine-induced synaptic depression at inhibitory synapses.

iScience June 20, 2025 Michelle K Piazza, Abigael R Weit, Ege T Kavalali et al. 2 citations

Ketamine induces antidepressant action via upregulation of hippocampal brain-derived neurotrophic factor (BDNF) expression and TrkB receptor signaling. Rett syndrome (RTT), a neurodevelopmental disorder caused by mutations in Methyl-CpG-binding protein 2 (MECP2), is associated with decreased BDNF expression. Although treatment with ketamine or LM22A-4, a TrkB receptor agonist, improves...

DOI: 10.1016/j.isci.2025.112485 (opens in new tab) Full text (opens in new tab) Ketamine Biological sciences Molecular neuroscience Natural sciences +3

Beyond surgery: Repurposing anesthetics for treatment of central nervous system disorders.

Progress in Neuro-Psychopharmacology and Biological Psychiatry June 20, 2025 Joana Mielko, Julia Pakulska, Amelia Oszczyk et al.

The development of new drugs is a complex, expensive, and time-consuming process, often fraught with a high likelihood of failure. Amid these obstacles, drug repurposing, which identifies new therapeutic applications for already existing medications, offers a more economical and time-saving approach, particularly in the challenging field of neurological and psychiatric disorders. This narrative...

DOI: 10.1016/j.pnpbp.2025.111386 (opens in new tab) Full text (opens in new tab) Drug repurposing Neurological disorders Neuropsychiatric disorders Anesthetics anaesthetics +5

“Diversity makes the richness of humanity”: The emergence and persistence of mental imagery after self-reported psilocybin truffles intake in an autistic woman with “blind imagination” (aphantasia): A 33-month retrospective case report

Journal of Psychedelic Studies June 17, 2025 Kevin Rebecchi

Abstract This 33-month retrospective case report explores the impact of psilocybin truffle intake on the emergence (and persistence) of mental imagery in an autistic woman with aphantasia. Aphantasia refers to the inability to generate visual mental images, which can significantly affect individuals' experiences and cognitive processes. The case study focuses on a 34-year-old autistic woman who...

The Reflexive Integrated Information Unit: A Differentiable Primitive for Artificial Consciousness

arXiv Preprint Archive June 15, 2025 Gnankan Landry Regis N'guessan, Issa Karambal preprint

Research on artificial consciousness lacks the equivalent of the perceptron: a small, trainable module that can be copied, benchmarked, and iteratively improved. We introduce the Reflexive Integrated Information Unit (RIIU), a recurrent cell that augments its hidden state $h$ with two additional vectors: (i) a meta-state $μ$ that records the cell's own causal footprint, and (ii) a broadcast...

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology June 15, 2025 Daniël Hoyer 9 citations

Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N , N ‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g. ibogaine, ketamine and esketamine; and other atypicals e.g. dextromorphan/bupropion, esmethadone....